NCT01411696View on ClinicalTrials.gov

Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)

CompletedOBSERVATIONAL
Enrollment

289

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Retinal Vein OcclusionMacular Edema
Interventions
DRUG

dexamethasone intravitreal implant 0.7 mg

Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.

Trial Locations (1)

Unknown

San Antonio

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY